Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin

Endocrine volume 42, pages754–755(2012)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

References

  1. 1.

    E. Scorletti, P.C. Calder, C.D. Byrne, Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40, 332–343 (2011)

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    G. Li Volti, S. Salomone, V. Sorrenti, A. Mangiameli, V. Urso, I. Siarkos, F. Galvano, F. Salamone, Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice. Cardiovasc. Diabetol. 14, 62 (2011)

    Article  Google Scholar 

  3. 3.

    L. Abenavoli, Role of silymarin to treat fibrosis development in non-alcoholic fatty liver disease. Hepatol. Res. 41, 668 (2011)

    PubMed  Article  Google Scholar 

  4. 4.

    N.E. Gulcelik, A. Usman, A. Gürlek, Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine 36, 397–403 (2009)

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    R. Wang, Q. Lu, J. Feng, F. Yin, C. Qin, B. Liu, Y. Liu, X. Liu, Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males. Endocrine 41, 70–75 (2012)

    PubMed  Article  Google Scholar 

Download references

Competing interests

The authors declare that they have no competing interests.

Author information

Affiliations

  1. Department of Health Sciences, University “Magna Græcia”, Viale Europa, 88100, Catanzaro, Italy

    Ludovico Abenavoli

  2. Department of Pharmacy, University of Novi Sad, Hajduk Veljkova 3, 21000, Novi Sad, Serbia

    Natasa Milic

  3. Department of Experimental Pharmacology, University “Federico II”, Via D. Montesano, 49, 80131, Naples, Italy

    Francesco Capasso

Authors
  1. Ludovico Abenavoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natasa Milic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Capasso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ludovico Abenavoli.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Abenavoli, L., Milic, N. & Capasso, F. Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin. Endocrine 42, 754–755 (2012). https://doi.org/10.1007/s12020-012-9677-0

Download citation

Keywords

  • Insulin Resistance
  • Silymarin
  • Free Fatty Acid Level
  • Silibinin
  • Favorable Safety Profile